**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71264

**Title:** Case report and review of dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease.

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 05402718

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Assistant Professor, Research Associate

**Reviewer’s Country/Territory:** China

**Author’s Country/Territory:** Australia

**Manuscript submission date:** 2021-09-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-09-02 00:11

**Reviewer performed review:** 2021-09-13 09:31

**Review time:** 11 Days and 9 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[ ] Scientific quality: [ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish

[ ] Language quality: [ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection

[ ] Conclusion: [ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection

[ ] Re-review: [ ] Yes [ ] No
SPECIFIC COMMENTS TO AUTHORS
In the present study, Au et al. presented Safety of dual biologic therapy in a patient receiving ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease. A case report and literature review update. Comments for authors. 1. Title, “A case report and literature review update”, it is hard to understand. I can’t see literature review update. 2. Abstract, “There were no adverse reactions for the duration of treatment”, the authors should present the case more gentle. How to proof that “no adverse reactions”? 3. Introduction, “Furthermore, the COVID-19 pandemic presents new challenges in the clinical setting with concerns to the safety of biologic therapy”, please supply references. 4. The language is needed to be improved. There are some mistakes for the grammar and language problems. For example, line 113, “stricturing” is a wrong word. 5. Line 140, “Unfortunately, 5 months in to therapy she developed diarrhoea despite having therapeutic levels of vedolizumab of 33 ug/mL”, could you please give the discussion for the developed diarrhoea. This should be adverse reactions, which is inconsistent to the point 1. 6. Except CRP, whether there are other indexes, such as inflammatory factors (IL-6), oxygenation index. 7. The ethical approval document is lacked. 8. “Funding, Nil.”, please provide the full name of Nil.. 9. There are no figures and tables, this case needs more evidences.
Name of journal: World Journal of Clinical Cases

Manuscript NO: 71264

Title: Case report and review of dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease.

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05852316
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Australia

Manuscript submission date: 2021-09-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-28 01:25

Reviewer performed review: 2021-09-28 02:51

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ Y] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [ Y] Yes | [ ] No |
SPECIFIC COMMENTS TO AUTHORS
In the present study, Au et al. presented Safety of dual biologic therapy in a patient receiving ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease. A case report and literature review update. Comments for authors 1. The ethical approval document is lacked. 2. Line 112 “A 45-year-old female with a four-month history of newly diagnosed ileal CD “ How to diagnose diagnosed ileal CD? Pathological diagnosis? 3. Line 147. 148 “ To date, the patient has safely received five months of DBT without adverse side-effects.” The case will been taken longer to observe the patient’s curative effect. 4. The literature review update isn’t been seen in the article. 5. Except CRP, whether there are other indexes, such as inflammatory factors (IL-6), oxygenation index. The article is not detailed. The case of the article is too simple. There are no figures and tables, this case needs more evidences.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases
Manuscript NO: 71264
Title: Case report and review of dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease.
Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 05852316
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: China
Author’s Country/Territory: Australia
Manuscript submission date: 2021-09-01
Reviewer chosen by: Jia-Ru Fan
Reviewer accepted review: 2021-11-25 07:48
Reviewer performed review: 2021-11-26 02:00
Review time: 18 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Peer-reviewer      | Peer-Review: [ Y] Anonymous  | [ ] Onymous |


SPECIFIC COMMENTS TO AUTHORS

Dual biologic therapy can offer new treatment strategies in patients with Crohn’s disease and in patients with different immune-mediated conditions. This case report should be valuable.